The active substance in their candidate drug ROSGard shows a strong renal protective effect in connection with radiation therapy (PRRT) in a short-term preclinical study with an animal model.

During the autumn of 2016, A1M Pharma chose kidney protection in connection with molecular targeted therapy to treat tumours (PRRT) as their first clinical application within acute kidney injury (AKI). PRRT is often used to treat aggressive endocrine cancer tumours in the gastrointestinal tract and the lungs. The treatment’s severe effect on the patients’ kidneys limits the maximum radiation dose that can be used, both in separate radiation treatments and in total. The aim is to administer the company’s candidate drug ROSGard to patients in connection with each radiation therapy session in order to increase the efficacy of the treatment while protecting the kidneys.

A1M Pharma has already observed a strong renal protective effect in preclinical studies with an animal model when the active substance in ROSGard is administered in connection with radiation therapy. So far, the renal protective effect has been studied 1-8 days after treatment.

“The strong renal protective effect of the active substance in ROSGard in this short-term preclinical study is very encouraging, although it is important to emphasize that we are still in early preclinical phase. The results strengthen our conviction that kidney protection in connection with targeted radiation therapy was a correct choice as our first clinical application within acute kidney injury. I am looking forward to present more conclusive results by the end of Q1 2017 when the data six months after treatment is expected to be available”, says A1M Pharma’s Head of Development Eddie Thordarson.

Results of the effect 6 months after treatment are expected by the end of Q1 2017.